⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551189 | 1.00 | — | — | |
| SCHEMBL3856133 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL3544180 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL708359 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL708358 | 0.98 | — | — | |
| SCHEMBL708271 | 0.89 | — | — | |
| SCHEMBL118100 | 0.89 | — | — | |
| SCHEMBL51793 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL1223341 | 0.87 | CYP3A4 (0.44) | — | |
| SCHEMBL40034 | 0.87 | CYP3A4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112939960-B | Carbonyl azetidine substituted NBD fluorescent dye and synthetic method and application thereof | 中国科学院大连化学物理研究所 | 2023-04-14 | — | — | CN | claimed |
| CN-112939936-B | Carbonyl azetidine substituted naphthalimide fluorescent dye and synthetic method and application thereof | 中国科学院大连化学物理研究所 | 2022-11-15 | — | — | CN | claimed |
| CN-112939960-A | Carbonyl azetidine substituted NBD fluorescent dye and synthetic method and application thereof | 中国科学院大连化学物理研究所 | 2021-06-11 | — | — | CN | claimed |
| US-20250136581-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | disclosed |
| CN-115703765-B | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250057957-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483875-A2 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2024-12-12 | — | — | US | disclosed |
| EP-3454862-B1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12048748-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| EP-4385988-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| US-6544976-B1 | Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-08 | — | — | US | disclosed |
| CN-1350522-A | new method | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
| WO-2001004091-A1 | NEUROTROPHIC 2-AZETIDINECARBOXYLIC ACID DERIVATIVES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-4178286-A | β-Lactams, their production, intermediates thereto and derivatives thereof | RESEARCH CORPORATION (US) | 1979-12-11 | — | — | US | disclosed |